Dantrolene
Dantrolene sodium is a muscle relaxant that is currently the only specific and effective treatment for malignant hyperthermia. It is also used in the management of neuroleptic malignant syndrome, muscle spasticity (eg. after strokes, in paraplegia, cerebral palsy, or patients with multiple sclerosis) and ecstasy intoxication.
Chemistry
Chemically it is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin.
The related substance azumolene is under development for similar indications. It has a bromine residue instead of the nitrite group, and is 30 times more water-soluble.
Mode of action
Dantrolene depresses excitation-contraction coupling in skeletal muscle by binding to the ryanodine receptor, and decreasing intracellular calcium concentration.
Contraindications
If the indication is a medical emergency such as malignant hyperthermia, the only significant contraindication is hypersensitivity.
Pregnancy and Lactation
Side-effects
CNS side effects are quite frequently noted and encompass speech and visual disturbances, mental depression and confusion, hallucinations, headache, insomnia and exacerbation or precipitation of seizures, and increased nervousness. Infrequent cases of respiratory depression or a feeling of suffocation have been observed. Dantrolene often causes sedation severe enough to incapacitate the patient to drive or operate machinery.
Gastrointestinal effects include bad taste, anorexia, nausea, vomiting, abdominal cramps, and diarrhoea.
Hepatic side effects may be seen either as asymptomatic elevation of liver enzymes and/or bilirubin or, most severe, as fatal and nonfatal hepatitis. The risk of hepatitis is associated with the duration of treatment and the daily dose. In patients treated for hyperthermia, no liver toxicity has been observed so far.
Pleural effusion with pericarditis (oral treatment only), rare cases of bone marrow damage, diffuse myalgias, backache, dermatologic reactions, transient cardiovascular reactions, and crystalluria have additionally been seen. Muscle weakness may persist for several days following treatment.
Mutagenicity and Carcinogenity
Dantrolene gave positive results in animal high dose studies (with and without enzymatic activation) regarding mutagenicity and carcinogenity. No evidence for human mutagenicity and carcinogenity has been found during the long years of clinical experience.
Drug Interactions
Dosage
The starting dose in oral treatment is 25 mg once daily, slowly increased to the optimal daily dose for the patient. Doses of up to 400 mg may be used, but not for more than 2 months.
The dosage in hyperthermia and other cases of emergency is strictly individual.
MEDIC8®: a-z of diseases
Clinics & treatments
Medic8® Guides
- Cosmetic Surgery
- Cosmetic Dentistry
- Weight Loss Surgery
- Laser Eye Surgery
- Laser Hair Removal
- Health Insurance
- Life Insurance
- Family Health
- Travel Health
Health centres
- Allergies
- Alternative Health
- Arthritis
- Asthma
- Blood Disorders
- Bones & Joints
- Bowel & Abdominal Problems
- Cancer
- Chest Problems
- Child Health
- Circulation Problems
- Diabetes
- Diet & Nutrition
- Drug Addiction
- Ear, Nose, & Throat Problems
- Elderly Health
- Eye Problems
- Heart Problems
- High Blood Pressure
- Hormone & Endocrine Problems
- Infections
- Infertility
- Liver Problems
- Medications
- Men's Health
- Mental Health
- Nervous System
- Personal & Social Issues
- Pregnancy & Birth
- Preventive Health
- Radiology
- Sexual Health
- Skin Problems
- Sports Medicine
- Surgery
- Travel Health
- Urinary & Kidney Problems
- Vaccination
- Women's Health

